Clinical and Therapeutic Effectiveness of Nanoscale Antibacterial Drugs for Veterinary Use

Abstract

Listen

Translate article

AbstractThe article presents some results of a comparative clinical and therapeutic evaluation of antibacterial drugs effectiveness based on exosomal and chitosan nanoparticles for veterinary use. To study the comparative clinical and therapeutic effectiveness of drugs based on exosomal and chitosan particles, three groups of lambs with diagnosed acute catarrhal bronchopneumonia were formed. Azitronite 10% at a dose of 1 ml per 20 kg of animal weight with an interval of 24 h was used as a reference antibacterial drug in the control group. Animals of the test groups were administered intramuscularly antibacterial drugs based on exosomal and chitosan particles at a dose of 0.5 ml per 10 kg of animal weight13-15,. The procedure was performed single administration. Animals’ condition was monitored throughout the study. It was found that the treatment of lambs with diagnosed acute bronchopneumonia with “Exasit” and “Chitasit” drugs at a dose of 0.5 ml/10 kg, single administration, contributed to a decrease in body temperature to the physiological norm values ​​and improved the general condition of the animals 1–2 days earlier than in the control group. Morphobiochemical blood parameters indicate that the reference values ​​were reached by the day 7 of the study, and in the control group, the normalization of indicators occurred only by the days 14–21. Thus, there is a significant advantage of the drugs “Exasit” and “Chitasit” in comparison with their analog, which is expressed in reducing the administration frequency of the antibacterial drug and the treatment duration.KeywordsSustainabilityAntibacterial drugsNanoparcleExosomalChitosanBronchopneumonia